Clearthesis
Sign inSign up

Sign up free to access investment thesis for 500+ leading US stocks

AppleAppleMicrosoftMicrosoftNvidiaNvidiaAmazonAmazonAlphabetAlphabetMetaMetaTeslaTeslaBroadcomBroadcomAMDAMDTSMCTSMCArmArmQualcommQualcommMicronMicronMarvellMarvellOracleOracleAdobeAdobeSalesforceSalesforceServiceNowServiceNowCrowdStrikeCrowdStrikePalo AltoPalo AltoSpotifySpotifyCloudflareCloudflareShopifyShopifyVisaVisaMastercardMastercardRobinhoodRobinhoodCoinbaseCoinbasePalantirPalantirBerkshireBerkshireCostcoCostcoWalmartWalmartNetflixNetflixJPMorganJPMorgan
View all covered stocks →
Clearthesis
PrivacyTermsContact

© 2026 ClearThesis, Inc.

For informational purposes only. Not investment advice. ClearThesis is not a registered investment adviser.

Following ENSG. You will receive monthly updates on how the investment thesis is playing out.
ENSG

The EnsignENSG

$181.65-0.1%
Updated Aug 16, 2026
Quality Score
4.1
Follow

On this page

Moat
Strong
Profitability
Strong
Management
Excellent
Revenue growth
Solid
Valuation
Attractive
Sentiment
Bullish

Our thesis

  • The Ensign is a healthcare operator that specializes in turning around underperforming skilled nursing facilities and senior living centers across a growing 17-state footprint. It generated $5.06 billion in revenue last year, up 18.8% from the year prior, while managing a massive portfolio of 398 separate healthcare operations.
  • The company wins by applying a decentralized leadership model to a heavily fragmented industry, which allows it to acquire struggling facilities and improve their clinical outcomes and profitability. Its repeatable acquisition machine is supported by a growing real estate arm called Standard Bearer that now owns 183 properties, giving the company high control over its physical assets and a secondary source of compounding value.
  • The main growth driver is the continued scaling of the Standard Bearer REIT alongside an aggressive pace of skilled nursing acquisitions in high-growth markets like Texas. This strategy recently led management to raise its 2026 revenue guidance to nearly $5.9 billion as record occupancy levels and clinical improvements across 102 newly acquired facilities since 2024 begin to pay off.
  • The Ensign trades at approximately 23 times next year’s earnings, which looks attractive for a high-quality compounder growing its bottom line at a mid-teens rate. This multiple is reasonable because the business consistently converts clinical excellence into higher reimbursement rates and better occupancy than its peers, providing a more durable earnings profile than typical healthcare operators.
  • The biggest risk is the intense regulatory pressure and labor cost inflation inherent to the skilled nursing industry, which could squeeze margins if government reimbursement rates fail to keep pace. We maintain a positive view because the company has a long history of raising guidance and successfully integrating large portfolios while maintaining superior clinical star ratings.

Metrics we are tracking

Metric
Expectations
Status
Same-Facility Occupancy
Staying above 83% for four consecutive quarters
84.1% in Q2 2026
Skilled Mix Revenue
Maintaining skilled nursing revenue above 50% of total service revenue
50.0% in Q2 2026
Standard Bearer Property Count
Adding 15 to 25 new real estate assets annually
183 assets as of Q2 2026
Adjusted EPS Growth
Sustaining year-over-year growth of 15% or higher
20.8% YoY in Q2 2026

Numbers at a glance

Scale

Stock Price

$181.65

Market Cap

$10.6B

Revenue (TTM)

$5.5B

Rev. 5-yr CAGR

17.8%

Performance

ROIC

7.3%

Gross Margin

14.1%

Op. Margin

8.4%

FCF Margin

7.6%

Valuation

P/E

27.6x

EV/EBITDA

20.2x

P/FCF

25.3x

Analyst Target

$215

Quality scorecard

The Ensign is a disciplined operator that has mastered the acquisition and turnaround of skilled nursing facilities. The key constraint is the company's dependence on government reimbursement rates which could squeeze margins during high inflation.

4.1
Moat Strength4

Real estate ownership via Standard Bearer and superior clinical outcomes create high barriers for local competitors.

Capital Efficiency4

ROE of 16.5% and ROIC of 7.1% reflect consistent returns on turnaround investments in a low-margin sector.

Revenue Growth5

Revenue grew 17.3% in the latest quarter, driven by aggressive acquisitions and record occupancy.

Growth Runway4

Massive fragmentation in the $180 billion SNF market provides years of consolidation opportunity ahead.

Management5

Barry Port has led a decade of consistent guidance raises and disciplined capital allocation.

AI Resilience3

AI has limited impact on the core physical care model but offers minor administrative tailwinds.

Risk Resilience4

Skilled nursing has faced intense labor and regulatory stress, yet Ensign has expanded margins throughout.

Business Overview

What does it do?

The Ensign is a growth business that earns money by providing professional nursing and rehabilitative care through its 398 affiliated healthcare operations. The company primarily generates revenue through its Skilled Services segment, where it provides short-term and long-term nursing care, physical therapy, and other post-acute services. Money flows through a mix of government and private payors, with the company receiving daily rates for each resident. Unlike centralized healthcare chains, Ensign uses a decentralized model where local administrators have the autonomy to make decisions, which helps them tailor care to their specific communities and improve local referral relationships.

Where does revenue come from?

The vast majority of revenue is generated from skilled services, though the company is rapidly growing its real estate rental income through its captive REIT. In Q2 2026, skilled services accounted for $1.43 billion in revenue, representing approximately 97% of the total mix. The remaining revenue comes from rental income via Standard Bearer, which leases facilities to both Ensign-affiliated and third-party operators. Geographically, the company operates across 17 states, with a heavy and expanding presence in Texas.

Revenue Breakdown

TOTAL$5.0B
Skilled Services Segment$4.8B97.4%
Standard Bearer Segment$127M2.6%

Who are its customers?

The Ensign serves tens of thousands of residents across 398 operations, including 348 skilled nursing facilities and 32 campuses that offer both nursing and senior living. The company’s financial success is driven by its "skilled mix," which represents patients requiring higher levels of care typically paid for by Medicare or managed care plans. In Q2 2026, same-facility occupancy reached 84.1%, an increase of 2.7% over the prior year. The company also tracks "skilled mix nursing days," which stood at 31.0% of total days this quarter, a key indicator that it is attracting the high-acuity patients that drive better reimbursement rates.

What gives it staying power?

The Ensign has staying power because its "Standard Bearer" real estate strategy ensures long-term control over its facilities while its superior clinical outcomes drive higher referral rates. By owning 183 of its own buildings, the company avoids the rising rent costs that often cripple other nursing home operators.

Where is it headed?

The company is making a major strategic bet on aggressive market expansion in Texas, having recently added 20 new operations in the state. Management is focused on applying its turnaround playbook to these new assets, which currently have lower occupancy than the company average. If successful, these acquisitions will provide a multi-year tailwind to earnings as they reach the higher profitability levels of Ensign's mature facilities.

Financial Performance

Bold sentence: Revenue is growing at a double-digit pace as the company successfully integrates a record number of new facility acquisitions. Revenue grew 17.3% YoY in the most recent quarter to $1.44 billion, driven by both new facility additions and a 2.7% increase in same-facility occupancy. This growth is accelerating as the company’s 2024 and 2025 acquisition cohorts move from the transition phase into full operational maturity.

Revenue
↑ Accelerating
$5.1B · +17.8% CAGR · +18.8% YoY

Bold sentence: Cash generation remains healthy with $272 million in operating cash flow over the first half of 2026 supporting an aggressive investment strategy. Free cash flow typically tracks net income well, though the company is currently deploying significant capital into real estate acquisitions for its Standard Bearer segment. This high CapEx is a strategic choice to own the underlying real estate of its operations rather than a burden of the core business model.

Earnings (Net Income)
↑ Growing
$0.3B · +13.3% YoY
Free Cash Flow
↑ Growing
$0.4B · +94.7% YoY

Bold sentence: The balance sheet is resilient with over $262 million in cash and nearly $600 million in available credit to fund the next leg of growth. While the company carries $2.1 billion in lease liabilities, its actual long-term debt is a manageable $135 million. This financial flexibility allows Ensign to remain the "buyer of choice" when underperforming portfolios come to market in a fragmented industry.

**Bold sentence: The Ensign is a financially dominant operator that has turned the low-margin skilled nursing industry into a high-growth, predictable earnings machine through superior occupancy and real estate control.

Margins
→ Stable
Op. CF 11.2%
Op. Cash Flow
What's Working Well

Occupancy and skilled mix are both reaching record levels, with same-facility occupancy hitting 84.1% in the most recent quarter. This improvement demonstrates that Ensign is winning market share from competitors by delivering superior clinical outcomes, which in turn leads to higher Medicare and managed care referrals. The model of acquiring "troubled" facilities and stabilizing them is working at a larger scale than ever before.

What to Watch

Labor cost management remains the primary risk, as nursing shortages could force a reliance on expensive contract labor. While Ensign reports that its turnover is significantly lower than industry averages, any sudden spike in wages or a shift in government reimbursement rates could temporarily compress margins. Investors should monitor the gap between Medicaid rate increases and the company's internal cost of services.

Moat & Competition

Industry Stage
Consolidating Industry
EMERGINGGROWTHCONSOLIDATINGMATUREDECLINING

The US skilled nursing and healthcare facility market is roughly $180 billion today and is on track to exceed $220 billion by 2029 as the aging population increases demand for post-acute care. While the industry is heavily regulated and faces structural pricing pressure from government payors, it is highly fragmented, offering a massive roll-up opportunity. The Ensign stands as the premier consolidator in this space, using its superior clinical outcomes to win favor with regulators and referral partners.

The Competition

The competitive dynamic in skilled nursing is brutally difficult due to fixed reimbursement rates and intense local competition for clinical staff. Success depends entirely on operational efficiency and the ability to maintain high star ratings to attract Medicare patients. Winning in this market requires a scale advantage that most smaller, independent operators simply cannot replicate.

BKD
Brookdale Senior LivingBKD
EHC
Encompass HealthEHC
SBRA
Sabra Health Care REITSBRA

Competitors like Brookdale and Encompass Health attack from different angles, with Brookdale focusing on senior housing and Encompass on high-intensity rehab. The most dangerous threat to Ensign is the rising cost of clinical labor, which rivals may bid up to fill their own facilities. Many smaller competitors are currently struggling with debt, allowing Ensign to acquire their best assets at attractive prices.

The Ensign is actively gaining share as it transitions 102 new operations into its portfolio, significantly outpacing the growth of its largest public peers.

The Moat
Moat Strength
Narrow Moat
Skilled nursing is a commodity service, but Ensign's real estate ownership and localized leadership model create high switching costs and operational barriers.
Trajectory
↗Widening
Acquisitions of underperforming facilities are being turned around faster than in prior cycles, proving the model scales efficiently.

The primary source of protection is a cost advantage combined with intangible assets in the form of its proprietary "turnaround playbook" and localized management culture. By owning 183 of its own properties, Ensign avoids the predatory rent escalators that have bankrupted other operators. This real estate integration allows the company to operate with lower structural overhead than its peers.

Collective metrics like an 84.1% occupancy rate and a 16.5% return on equity prove that Ensign's advantage is real and durable. These numbers are consistently higher than the industry average, showing that the company’s decentralized model actually results in better care and higher profits. The combination of superior clinical ratings and real estate control confirms a Narrow moat exists.

The rating is capped at Narrow because the company remains heavily dependent on government reimbursement rates, which it cannot control. While the operational excellence is high, a major change in Medicare policy could still damage the business.

The moat is strengthening as the Standard Bearer REIT grows, which provides the company with increasing control over its physical footprint and long-term costs.

Management

Management Quality
Strong
B
Barry R. Port
Chief Executive Officer
Execution
High

Raised 2026 earnings guidance twice in six months following consecutive earnings beats.

Capital Allocation
Disciplined

Acquired 102 new operations since 2024 while maintaining over $850 million in total liquidity.

Alignment
High

Barry Port and other insiders hold significant stakes and have a long history of dividend increases.

Capital Allocation Track Record

Accelerated acquisition of 20 new Texas operations to capitalize on state-level reimbursement tailwinds.
Continued scaling of Standard Bearer REIT to 183 properties, reducing reliance on third-party landlords.
Successful integration of "transitioning" facilities, raising their occupancy by 2.3% year-over-year.

Management is exceptional at capital allocation, having built a repeatable machine that buys distressed healthcare assets and turns them profitable within 24 months. CEO Barry Port and Executive Chairman Christopher Christensen have maintained a culture of decentralized local leadership that is rare in healthcare, allowing the company to attract and keep top-tier facility administrators. Their focus on clinical excellence as the primary driver of financial results has earned them the trust of both regulators and investors.

The key-person risk is moderate given the long tenure of the founding team, but the company has a deep bench of leaders developed through its own Service Center. The board is independent and has overseen a decade of consistent dividend growth and share price appreciation. Governance is a strength here, as the company’s captive insurance and real estate subsidiaries are structured to protect the core operating business from the volatility of the broader healthcare market.

Market view

Average target$215+18%vs $181.65 today
TodayAvg price
Low $202High $228
Strong Buy12 analysts
0Bearish
2Neutral
10Bullish
FirmRatingPrice TargetDate
RBC Capital
PT Raised
$222→$228
7/28/2026
Truist Financial
PT Lowered
$215→$202
7/14/2026
RBC Capital
PT Raised
$206→$222
2/9/2026
Truist Financial
PT Raised
$200→$215
2/6/2026
UBS
PT Raised
$220→$230
2/6/2026
RBC Capital
PT Raised
$206
11/14/2025
Truist Financial
PT Raised
$190→$200
11/10/2025
UBS
PT Raised
$205→$220
11/5/2025

Outlook: Growth and risks

We expect revenue to grow from $5.9B in FY2026 to $8.9B in FY2031 (~9% CAGR), with EPS growing from $7.79 to $12.20 (~9% CAGR). Revenue grows as the company acquires and improves underperforming skilled nursing facilities across a fragmented market. Operating margins expand as the company applies its standardized management platform to newly acquired facilities, spreading corporate overhead across more beds. EPS grows faster than revenue because the company consistently buys back shares and improves the profitability of its real estate portfolio. Operating margin expected to reach ~10% by FY2031.

Projected revenue and EPS growth
FY2026
FY2027
FY2028
FY2029
FY2030
FY2031
Revenue
$5.9B
$6.5B
+10%
$7.1B
+9%
$7.7B
+8%
$8.3B
+8%
$8.9B
+8%
EPS (diluted)
$7.79
$8.55
+10%
$9.37
+10%
$10.25
+9%
$11.19
+9%
$12.20
+9%
Growth Drivers

Standard Bearer REIT becomes a major independent value driver. Scaling the real estate arm to own 250+ properties would unlock massive asset value and further lower operational rent expenses.

Texas acquisition cohort reaches mature occupancy and margin levels. If the 20 newly acquired Texas facilities match the 84% occupancy of mature sites, it would add significant high-margin revenue.

Managed care skilled mix continues to expand in core markets. Deepening relationships with private insurers for post-acute care drives higher daily rates than traditional government Medicaid.

Risks

Federal or state reimbursement rates fail to track labor inflation. If Medicare or Medicaid rates are frozen while nursing wages spike, the company’s turnaround margins would compress across all facilities.

Large-scale legal or regulatory action targets the skilled nursing industry. Ongoing law firm investigations into securities laws or potential new federal staffing mandates could increase compliance costs significantly.

High interest rates increase the cost of future real estate acquisitions. Rising borrowing costs could slow the pace of the Standard Bearer roll-up strategy, limiting the company's ability to own its buildings.

Metrics to Watch
  • •Same-Facility OccupancyStaying above 83% for four consecutive quarters
  • •Skilled Mix RevenueMaintaining skilled nursing revenue above 50% of total service revenue
  • •Standard Bearer Property CountAdding 15 to 25 new real estate assets annually
  • •Adjusted EPS GrowthSustaining year-over-year growth of 15% or higher

Valuation

Below is our estimate of current and future fair value, with detailed reasoning and assumptions. Fair value is a judgment, not a fact, and other analysts will likely land on different numbers. Use it as one data point in your research, and apply your own discretion in any investing decision.

Our Stance
High conviction
Bullish

The Ensign Group is worth $222 per share, representing a 22% potential return as the company converts its healthcare operations into a dominant clinical and real estate platform with industry-leading occupancy and profit margins.

Fair Value
Current Price
$222
$182
$200$244
fair value range
Undervalued
Where could this stock be in 5 years?
Bull
$391
+115% vs today
Base
$268
+48% vs today
Bear
$143
-21% vs today
20272028202920302031
EPS$8.55$9.37$10.25$11.19$12.20
P/E26x25x24x23x22x
Price$222$234$246$257$268
How is the fair value calculated?

We use a Forward P/E approach, which applies a price-to-earnings multiple to next year's estimated profits. It fits Ensign Group because the company is consistently profitable and has a predictable earnings growth path, making "earnings power" a cleaner signal of value than revenue-based multiples.

Our fair value of $222 is calculated by multiplying the 2027 earnings estimate of $8.55 by a 26x multiple. This 26x multiple sits significantly above peers like Encompass Health (18x) and Tenet Healthcare (9x) because Ensign owns a massive real-estate portfolio through its REIT and consistently beats earnings estimates by over 4%. We use the FY2027 EPS of $8.55 provided in the deterministic projections to ensure this valuation aligns with the company's expected growth from recent Texas acquisitions.

Cross-check

A 5-year Discounted Cash Flow (DCF) cross-check produces a fair value of $256, which is about 15% higher than our Forward P/E answer. This independent check calculates value by estimating all future cash the company will generate and shrinking it back to today's dollars. The higher DCF value suggests our 26x P/E multiple may actually be conservative, as the DCF captures the long-term value of the real estate assets that a simple one-year earnings multiple might miss. We stick with the $222 figure as our primary target to remain disciplined in the face of current legal investigations.

What are the assumptions?

We're assuming the company maintains an average occupancy rate above 84% across its transition facilities. This is reasonable because same-facility occupancy reached 84.1% in the most recent quarter, and management has a proven 20-year track record of improving the utilization of newly acquired "troubled" facilities.

We're assuming the Standard Bearer REIT continues to grow its asset base by roughly 10% per year. With 181 real estate assets already owned, the company has demonstrated it can successfully shift from renting facilities to owning them, which provides a permanent cost advantage over competitors who are vulnerable to rising rent.

We're assuming annual revenue growth stays near 10% through 2028. This sits at the high end of the 5% industry average but is justified by Ensign’s aggressive acquisition strategy, including the recent expansion into Iowa and Texas which added nearly 400 operations to the portfolio.

Show all assumptions ▾
  • Current price: $181.65 (Brief, 2026-08-16)
  • Shares outstanding: 58.0M (Brief, 2026-08-16)
  • FY2027 EPS estimate: $8.55 (Deterministic Projections, 2026-08-16)
  • Net debt: $1.99B (Brief balance sheet, 2026-06-30)
  • TTM P/E: 27.6x (Brief, 2026-08-16)
  • Historical EV/EBITDA: 20.6x (Brief, 2026-08-16)
  • Peer P/E (Encompass Health): 18.5x (MarketBeat, 2026-08-16)
  • Peer P/E (Tenet Healthcare): 9.4x (MarketBeat, 2026-08-16)
What's the biggest risk?

The biggest risk is the ongoing legal investigation into potential securities law violations and fiduciary duty breaches. This could lead to a loss of investor confidence and a contraction in the valuation multiple from 26x to 20x, knocking roughly $50 off the per-share fair value. Watch for any formal SEC inquiries or class-action filings as the early signal.

What could change the price?
↓

Bear case ($188): Portfolio-wide occupancy drops below 80% for two consecutive quarters, signaling a breakdown in the local leadership growth model; or Legal investigations by the Rosen or Kaplan Fox firms uncover systemic billing issues, leading to significant financial penalties or loss of operating licenses.

↑

Bull case ($257): Standard Bearer REIT acquisitions exceed $400 million in a single fiscal year, accelerating the transition to a high-margin real estate ownership model; or Managed care contract rates increase by more than 5% annually, significantly expanding net margins above the current 7% ceiling.

Final Verdict

Buy

High convictionLong-term compounder

The Ensign has built a rare, repeatable growth machine in a fragmented and difficult industry by combining operational turnarounds with real estate ownership. The single most important reason for this verdict is the company's ability to consistently raise guidance while maintaining superior clinical outcomes. The biggest risk is a drastic shift in government reimbursement rates.

Get updates for ENSG

Share this investment thesis

Clearthesis wrote this report from 42 sources, including SEC filings, analyst estimates, industry research, and recent news.

Related stocks to explore

Other companies worth a closer look.

NVDA
Nvidia
NVDA
AAPL
Apple
AAPL
MSFT
Microsoft
MSFT
AMZN
Amazon
AMZN
GOOGL
Alphabet
GOOGL

How did you like this thesis?

Your feedback helps us make reports better for you

© 2026 Clearthesis.ai · Report generated on August 16, 2026

This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.

4Latest updatesFollow ENSG
Sign up free for more access
  • Undervalued stock ideas every week
  • Track this thesis as it changes
  • Ask the AI analyst anything
Sign up free
NEUTRALBEARISHBULLISHBullish